Breaking News

Incannex, Eurofins Enter Development & Mfg. Pact for Addiction Disorder Meds

Eurofins will provide formulation development and manufacture of chewable CannQuit Nicotine (CannQuit-N) and CannQuit Opioid (CannQuit-O).

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Incannex Healthcare Ltd., a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic therapies for unmet medical needs, has engaged multinational contract development and manufacturing organization (CDMO) Eurofins Scientific to manufacture Incannex’s two distinct medicated chewable products designed to treat nicotine and opioid addiction disorders.   The CannQuit products are combination drug assets that were transferred to Incannex as a result of the acquisition ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters